Article Text

other Versions

PDF
Research paper
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
  1. Stefanie Dahlhaus1,
  2. Robert Hoepner1,
  3. Andrew Chan1,
  4. Ingo Kleiter1,
  5. Ortwin Adams2,
  6. Carsten Lukas3,
  7. Kerstin Hellwig1,
  8. Ralf Gold1
  1. 1Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany
  2. 2Department of Virology, University of Duesseldorf, Duesseldorf, Germany
  3. 3Department of Radiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany
  1. Correspondence to Professor Ralf Gold, Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Gudrunstr. 56, Bochum 44791, Germany; ralf.gold{at}rub.de

Abstract

Objective Although the prognosis of natalizumab-associated progressive multifocal leukoencephalopathy (PML) seems to be better than HIV-associated PML, little is known about the long-term functional outcome in multiple sclerosis (MS) patients and the subsequent return of MS disease activity. We evaluated retrospectively 15 patients with natalizumab-associated PML treated at our centre.

Patients and methods Fifteen MS-PML patients (nine women, six men) were referred to us from adjacent local centres. The patients had a median natalizumab exposure of 34 months at PML diagnosis. They received standardised treatment as described in previous work. Expanded Disability Status Scale (EDSS) and Karnofsky score in the year pre-PML, at PML-diagnosis (pre-immune reconstitution inflammatory syndrome (IRIS)) and post-PML were determined in 3–6 monthly intervals.

Results The median follow-up of these 15 patients was 21.5 months. None of the 15 patients died. Three patients had a Karnofsky score of 80 or higher, nine patients between 50–70 and three patients of 40 or lower at latest examination. Eight of the 15 patients developed seizures during acute PML phase. Fifty percent of those patients were not seizure-free one year post PML, despite continuation of antiepileptic treatment. The median EDSS in the year pre-PML was 2.5, 4.5 at PML diagnosis, 6.5 post-IRIS and 5.5 at latest examination. CSF became virus-free in eight of the 15 patients after a median time of 4.5 months. In nine patients, disease reappeared after a median time of seven months from PML diagnosis.

Conclusions Although the clinical outcome of natalizumab-treated PML patients is much better than in patients with HIV-associated PML, this may be further improved by treatment at reference centres using standardised therapy regimens and transient intensive care if needed. Systematic studies of appropriate MS immunotherapies after PML are critically needed.

  • Multiple Sclerosis
  • Neurovirology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles